Core Insights - Avantor, Inc. reported a revenue of $1.62 billion for the quarter ended September 2025, reflecting a decline of 5.3% year-over-year and a surprise of -1.56% compared to the Zacks Consensus Estimate of $1.65 billion [1] - The earnings per share (EPS) for the quarter was $0.22, down from $0.26 in the same quarter last year, with an EPS surprise of -4.35% against the consensus estimate of $0.23 [1] Revenue Performance - Bioscience Production revenue was $527.3 million, slightly below the average estimate of $536.7 million, representing a year-over-year decline of 2.9% [4] - Laboratory Solutions revenue totaled $1.1 billion, compared to the average estimate of $1.11 billion, marking a year-over-year decrease of 6.4% [4] Operating Income - Adjusted Operating Income for Laboratory Solutions was reported at $123.6 million, below the average estimate of $134.01 million [4] - Adjusted Operating Income for Corporate was -$14 million, better than the average estimate of -$19.3 million [4] - Adjusted Operating Income for Bioscience Production was $127.7 million, compared to the average estimate of $134.34 million [4] Stock Performance - Avantor's shares have returned +20.8% over the past month, significantly outperforming the Zacks S&P 500 composite's +3.8% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Q3 2025 Earnings Earnings Presentation October 29, 2025 Disclaimer Forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this presentation are forward-looking statements. Forward-looking ...

Core Viewpoint - Avantor Inc. reported worse-than-expected second-quarter 2025 adjusted EPS, leading to a decline in stock price, with shares nearing their 52-week low [1]. Financial Performance - The company reported adjusted EPS of 24 cents, slightly below the consensus estimate of 25 cents [1]. - Sales for the quarter were $1.68 billion, nearly in line with the consensus of $1.675 billion, but fell 1% compared to the second quarter of 2024 [1][2]. - Net income decreased to $64.7 million from $92.9 million a year ago, while adjusted net income was $161.2 million compared to $168 million [5]. - Adjusted EBITDA was $279.8 million, down from $305.6 million, with a margin of 16.6% [5]. - Adjusted operating income fell from $277.2 million to $252.2 million, with a margin of 15.0% [6]. Segment Performance - Laboratory Solutions sales were $1.12 billion, a reported decrease of 3%, with a 1% organic decline [2]. - Bioscience Production sales were $561.3 million, also a reported decrease of 3%, but showed a 2% increase on an organic basis [3]. - The bioprocessing performance did not meet expectations due to planned maintenance at a manufacturing facility, despite strong demand for the monoclonal antibody platform [4]. Strategic Developments - The company announced significant actions to accelerate growth and enhance its cost structure, targeting $400 million in gross run-rate savings by the end of 2027 [6]. - A five-year contract extension with BIO Business Solutions was executed, positioning the company to benefit from future funding levels in the biotech industry [7]. Market Position - Avantor stock trades at approximately 10.8 times the 2025 EBITDA estimate, compared to peers at 15.4 times and its own average of 15.9 times as a public company [8]. - The company's growth and margin profile are considered below peer levels, justifying the current discount to peers [8].

Core Insights - Avantor, Inc. reported revenue of $1.68 billion for the quarter ended June 2025, reflecting a decrease of 1.1% year-over-year, with EPS at $0.24 compared to $0.25 in the same quarter last year [1] - The reported revenue met the Zacks Consensus Estimate, showing a surprise of +0.38%, while the EPS fell short of expectations by 4% [1] Revenue Breakdown - Bioscience Production revenue was $561.3 million, slightly below the estimated $568.43 million, marking a year-over-year increase of +2.6% [4] - Laboratory Solutions revenue reached $1.12 billion, exceeding the average estimate of $1.11 billion, but represented a year-over-year decline of -2.9% [4] Operating Income Analysis - Adjusted Operating Income for Laboratory Solutions was reported at $133.3 million, below the average estimate of $144.2 million [4] - Adjusted Operating Income for Corporate was -$20.8 million, worse than the average estimate of -$17.99 million [4] - Adjusted Operating Income for Bioscience Production was $139.7 million, slightly above the estimated $134.75 million [4] Stock Performance - Avantor's shares have returned -3.2% over the past month, contrasting with the Zacks S&P 500 composite's +2.3% change [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance relative to the broader market in the near term [3]